Dr Achim Rosemann

Email:

Research Fellow

I have an interdisciplinary background in medical anthropology, science and technology studies (STS) as well as China and East Asian studies, with fieldwork experience in China, Hong Kong, Taiwan and the UK. My research involves mixed method approaches that combine qualitative and quantitative methods. Generally, my research and publications today have focused on the following core areas.

(1)  The social, cultural and regulatory dimensions of developments in stem cell research and regenerative medicine, genomics research and human genome editing, with a geographic focus on developments in the wider China region, India, the UK and the USA. 

(2)  The interface of bioscientists, ‘publics’, corporations, academia and the state in comparative perspective, with a focus on processes of public participation and "co-production" against the backdrop of global inequalities as well as differences in political and innovation cultures

(3)  The subjective and experiential dimensions of biomedical innovation, i.e. the ways in which new medical inventions impact on the lives, experiences and perceptions of laypeople and patients, including the re-shaping of individual and collective identities and the creation of new forms of sociality, collective action and communities.

(4)  Responsible Innovation (RI) in the context of the biotech industry: emerging practices, understandings and challenges to the adoption and implementation of responsible innovation ideas in the private sector.

PUBLICATIONS

1. Academic Publications (Social Science and Life Science/Biomedical Journals as well as Book Sections)

Rosemann, A. and H.Y. Luo (2018) Attitudes on the Donation of Human Embryos for Stem Cell Research among Chinese IVF Patients and Students. Journal of Bioethical Inquiry. Doi.org/10.1007/s11673-018-9862-9. 

Jiang, L. and A. Rosemann (2018). Human embryo gene editing in China: the uncertain legal status of the embryo, Biosocieties. Doi.org/10.1057/s41292-018-0116-1.

Rosemann, A. (in press) Balancing social justice and risk management in the governance of gene drive technology: lessons from stem cell research. In: Hauskeller, C., Manzeschke, A., and A. Pichl (Eds). The Matrix of Stem Cell Research Revisited. Routledge. 

Rosemann, A., Bortz, G., and F. Vasen (2018). Regulatory developments for non-hematopoietic stem cell therapeutics: perspectives from the EU, the USA, Japan, China, India, Argentina and Brazil. In: X.D. Chen (ed.) A Roadmap to non-Hematopoietic Stem Cell-based Therapeutics: From the Bench to the Clinic. London and New York: Elsevier Academic Press. 

Rosemann, A., Jiang, L. and X.Q. Zhang (2018). The Regulatory and Legal Situation of Human Embryo, Gamete and Germ Line Gene Editing Research and Clinical Applications in the People’s Republic of China. Commissioned Background Paper. Nuffield Council of Bioethics. 

Sleeboom-Faulkner, M., Chen, H.D. and A. Rosemann (2017). Regulatory Capacity Building and the Governance of Clinical Stem Cell Research in China, Science and Public Policy, Doi.org/10.1093/scipol/scx077 

Rosemann, A., Barfoot, J. and C. Blackburn (2017) Special Focus Issue on Regenerative Medicine in Society: Interdisciplinary Perspectives (Part I) – ForewordRegenerative Medicine, 12(6), 577-580. (September Issue 2017). 

Barfoot, J., A. Rosemann and C. Blackburn (2017) Special Focus Issue on Regenerative Medicine in Society: Interdisciplinary Perspectives (Part II) – ForewordRegenerative Medicine, 12(7), 733-736. (October Issue 2017). 

Rosemann, A., Zhang Z.Q,, Sui, S.L., Ely, A., and Sleeboom-Faulkner, M.  (2017) The regulatory situation for stem cell research in China: basic, preclinical and clinical research. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer, 275-290.

Rosemann, A. (2017) Contested Tissues: the donation of oocytes and embryos in the IVF-Stem Cell Interface in China. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer, 291-300. 

Bortz, G., Vasen, F. and A. Rosemann (2017) Entre oportunidad y riesgo. Regulación, expectativas y políticas CTI para células madre en ArgentinaCiencia, Docencia y Tecnología, 54, 38-74.

Rosemann, A. (2017) Challenges to international stem cell clinical trials in countries with divergent regulations. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer, 301-319.

Pham, P.V., and A. Rosemann (2017) Safety, Ethics and Regulation - Preface. In: Pham, P.V. and A. Rosemann (eds.) Stem Cells in Clinical Applications: Safety, Ethics and Regulations. Heidelberg and New York: Springer.

Rosemann, A., L. Jiang and X.Q. Zhang (2017) Human Germ Line Gene Editing: Why comparative, cross-national studies on public viewpoints are important. Anthropology, DOI: 10.4172/2332-0915.1000175 

Sleeboom-Faulkner, M. Chekar, C. Faulkner, A. Heitmeyer, C., Marouda, M. Rosemann, A, et al. (2016) National Home-Keeping and the Regulation of Translational Stem Cell Applications: An international perspectiveSocial Science & Medicine, 153, 240-249 

Rosemann, A., Bortz, G., Vasen, F., and M. Sleeboom-Faulkner (2016) Global regulatory developments for clinical stem cell research: diversification and challenges to collaborationsRegenerative Medicine, 11(7), 647-657.

Rosemann, A. and N. Chaisinthop (2016) The pluralization of the international: networks of resistance and alter-standardization in regenerative stem cell medicine. Social Studies of Science, 46(1), 112-39.

Rosemann, A. and M. Sleeboom-Faulkner (2016) New regulation for clinical stem cell research in China – expected impact and challenges for implementation, Regenerative Medicine, Doi:10.2217/rme.15.80

Rosemann, A. (2015) ‘Stem cell treatments for neurodegenerative diseases: challenges from a science, business and healthcare perspective, Neurodegenerative Disease Management, 5(2), 85-87.

Rosemann, A. (2015) ‘Multi-country Stem Cell Trials: the Need for an International Support Structure', Stem Cell Research, 14(3), 396-400.

Rosemann, A. (2014) 'Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine', Social Science & Medicine, 122, 72-80.

Rosemann, A. (2014) ‘Why regenerative stem cell medicine progresses slower than expected', Journal of Cellular Biochemistry, 15(12), 2073-2076.

Rosemann, A. (2014) 'Modalities of value, exchange, solidarity: the social life of stem cells in China', in: M. Sleeboom-Faulkner (Ed.) Stem Cell Research in Asia: Looking beyond regulatory exteriors. London/New York: Routledge. 

Rosemann, A. (2013) 'Scientific Multipolarization: Its impact on international clinical research collaborations and theoretical implications', Science Technology and Society, 18(3), 339-359. 

Rosemann, A. (2013) `Medical Innovation and National Experimental Pluralism: Insights from Clinical Stem Cell Research and Applications in China', BioSocieties, 8(1), 58-74.

Rosemann, A. (2011) `Modalities of Value, Exchange, Solidarity: Exploring the Social Life of Stem Cells in China', New Genetics and Society, 30(2)2, 181-192.

Rosemann, A. (2010) 'The IVF-Stem Cell Interface in China: Ontologies, Value-perceptions and Donation-practices of Embryonic Forms of Life ', in O. Doering (ed.), Life Sciences in Translation - A Sino-European Dialogue on Ethical Governance of the Life Sciences, BIONET, Online Textbook, delivery to the EU Commission, 168-179.

Rosemann, A. (2009) `Life without Value? Listening to the voices of embryo donors for human embryonic stem cell research in China', The Newsletter, International Institute of Asian Studies, No 52, winter 2009, 15-6. (URL: http://sro.sussex.ac.uk/53217/).

 2. Special Issues and Edited Book Volumes

Rosemann, A., Barfoot, J., and C. Blackburn (2017) 'Regenerative Medicine in Society: Interdisciplinary Perspectives (Part 1)', Regenerative Medicine, 12(6), 577-731 [September issue 2017] (Press Release RegMedNet)

Barfoot, J., Rosemann, A., and C. Blackburn (2017) 'Regenerative Medicine in Society: Interdisciplinary Perspectives (Part 2)', Regenerative Medicine, 12(7), 733-892 [October issue 2017] (Press Release Eurekalert)

Pham, P.V., and A. Rosemann (2017) Stem Cells in Clinical Applications (Volume 6): Safety, Ethics and Regulation. Heidelberg and New York: Springer (Series Editor: Phuc Van Pham). ISBN 978-3-319-59164-3.

Rosemann, A. (in progress) ‘Alter-standardizing Clinical Trials’, Special Issue, Science as Culture  

3. Digital Resources and Online Publications 

EuroStemCell (2017). A Digital Gateway: Regenerative Medicine in Society. EuroStemCell Website: http://www.eurostemcell.org; Co-production with Jan Barfoot, Adam Price-Evans, Ryan Lewis, Anna Couturier, and Clare Blackburn. (Press Release EurekAlert) (Press Release RegMedNet).

This Digital Gateway comprises 27 short contributions of leading inter-disciplinary scholars written for patients, practitioners, and the wider public.

Rosemann, A., Barfoot, J., Price-Evans, A. and C. Blackburn (2017). Regenerative Medicine in Society – Introduction to the Digital Gateway

Rosemann, A. (2017) The Regulation of Clinical Stem Cell Research and Applications: three dynamics of global regulatory diversification. RegMedNet. Spotlight to Cell Therapy Regulation (June 30, 2017). (Part 1) (Part 2) (Part 3).

Rosemann, A. (2013) ‘Stem Cell Clinical Trials’, Centre for Bionetworking, Educational Resource (URL: http://sro.sussex.ac.uk/53219/)

4. Other Publications 

Rosemann, A. (2014) 'Multi-polar Technoscience: Clinical Science Collaborations in a Changing World System', PhD Dissertation.

5. Reports 

Rosemann, A. (2017) 'Germ Line Gene Editing in Global Context: Challenges and Needs from a UK Perspective', report for the Nuffield Council of Bioethics's Working Party: “Genome Editing in Human Reproduction.” 

Rosemann, A. (2015) ’Clinical stem cell research collaborations between China and the USA: opportunities, challenges, possible solutions’, client: Don Reed, Palo Alto, CA, USA (Californians for Cure; Sponsor of Roman Reed Spinal Cord Injury Research Act; CA)

Rosemann, A. (2014) ‘US FDA Regulation of Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P's), submitted to the ESRC.  

Rosemann, A., Zhang XQ., Sui SS., Su YY, and A. Ely (2013) 'Country Report: Stem Cell Research in China'; part of a working paper series of the Bionetworking in Asia Project, submitted to the ESRC.     

Rosemann, A. (2011) `Contextualizing Experimental Stem Cell Applications in China'; client: Department of Regulatory Affairs, Western Institutional Review Board (Western IRB), Olympia, USA

Rosemann, A. (2011) ‘Ethical Strategies in Stem Cell Banking: UK and Taiwan in cross-national Perspective', submitted to: Taiwan Stem Cell Bank, Hsinchu, Taiwan 

Rosemann, A. (2010) `ISBC Report: Stem Cell Research in Taiwan', submitted to the ESRC.

Rosemann, A. (2009) `BIONET/LSE Research Stipend: Final Report', submitted to the European Commission.